This has been the fastest recruiting clinical trial ever in the UK, and a testament to the
combined research capability of the National Health Service (NHS), National Institute for …

Purpose Molnupiravir is an oral antiviral agent authorized for emergency use to treat mild to
moderate cases of coronavirus disease 2019 (COVID-19) in adults at high risk for …

There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …

Background: Molnupiravir is a ribonucleoside analog and exhibits its antiviral mechanism by
inhibiting replication. Preclinical studies have been reported that support the role of …

The key goal of this mini review article is to provide enough data and info on the several
clinical trials conducted in some number of countries in the Asia on the use of the drug …

Methods Searches of the Clinical Trials Registry-India (CTRI) were conducted to find
registered trials of molnupiravir in India. Subsequent investigations were performed to …

The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …